Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of MSCs-Exos in Mild to Moderate Alzheimer's Disease
NCT04388982Phase 2Unknown
- Sponsor
- Ruijin Hospital
- Start
- Jul 2020
- Primary completion
- Aug 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of lotazadromcel in Alzheimer's disease (AD), sponsored by Ruijin Hospital. Status: unknown.
02
Drugs
lotazadromcel
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04388982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04388982.